Inadequate heart rate control is associated with worse quality of life in patients with coronary artery disease and chronic obstructive pulmonary disease. The RYTHMOS study

Hellenic Journal of Cardiology

Volumn 53, Issue 2, 2012, Pages 118-126

  Andrikopoulos, George ^a   Pastromas, Socrates ^b   Kartalis, Athanasios ^c   Toli, Konstantina ^d   Mantas, Ioannis ^d   Tzeis, Stylianos ^a   Kyrpizidis, Christos ^e   Olympios, Christoforos ^f   Manolis, Athanasios J ^g   Foussas, Stefanos ^h   Kranidis, Athanasios ⁱ   Pras, Athanasios ^j   Pipilis, Athanasios ^k   Chryssos, Dimitris ^l   Gotsis, Alexandros ^m   Trikas, Athanasios ⁿ   Richter, Dimitrios ^o   Alexopoulos, Dimitrios ^p   Parthenakis, Fragiskos ^q   Theodorakis, George ^a   Konstantinides, Stavros ^r   Vardas, Panos ^q   more..

^a HENRY DUNANT HOSPITAL   (Greece)

^b EVANGELISMOS HOSPITAL   (Greece)

^c Chios General Hospital   (Greece)

^d Halkida General Hospital   (Greece)

^e 2nd IKA Hospital Thessaloniki   (Greece)

^f THRIASIO GENERAL HOSPITAL   (Greece)

^g Asklipeion General Hospital Voula   (Greece)

^h Tzaneio General Hospital Piraeus   (Greece)

ⁱ Western Attica General Hospital   (Greece)

^j Chania General Hospital   (Greece)

^k HYGEIA HOSPITAL   (Greece)

^l Tripoli General Hospital   (Greece)

^m Komotini General Hospital   (Greece)

ⁿ Elpis General Hospital   (Greece)

^o Athens Euroclinic   (Greece)

^p UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^q UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^r DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

more..

Author keywords

Chronic pulmonary obstructive disease; Heart rate; Quality of life; Stable angina

Indexed keywords

AMIODARONE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; CARVEDILOL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IVABRADINE; METOPROLOL; NEBIVOLOL; NITRATE; STATIN; VERAPAMIL;

ADULT; AGED; ANGINA PECTORIS; ANGIOGRAPHY; ANGUILLA (COUNTRY); ARTICLE; BODY MASS; CARDIAC PATIENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EVALUATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; GEOGRAPHY; HEART FAILURE; HEART INFARCTION; HEART RATE; HEART RATE VARIABILITY; HOSPITAL; HUMAN; HYPERTENSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; OBSERVATIONAL STUDY; PATIENT SATISFACTION; PROGNOSIS; QUALITY OF LIFE; SPIROMETRY;

ADRENERGIC BETA-ANTAGONISTS; AGED; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; MALE; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; RISK FACTORS; TREATMENT OUTCOME;

EID: 84860208134     PISSN: 10117970     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Daly CA, De Stavola B, Sendon JL, et al. Predicting prognosis in stable angina--results from the Euro heart survey of stable angina: prospective observational study. BMJ. 2006; 332: 262-267.
2. Colin P, Ghaleh B, Monnet X, et al. Contributions of heart rate and contractility to myocardial oxygen balance during exercise. Am J Physiol Heart Circ Physiol. 2003; 284: H676-682.
3. Collins P, Fox KM. Pathophysiology of angina. Lancet. 1990; 335: 94-96.
4. Fox K, Borer JS, Camm AJ, et al. Resting heart rate in cardiovascular disease. J Am Coll Cardiol. 2007; 50: 823-830.
5. Palatini P, Julius S. Elevated heart rate: a major risk factor for cardiovascular disease. Clin Exp Hypertens. 2004; 26: 637-644.
6. Palatini P, Benetos A, Julius S. Impact of increased heart rate on clinical outcomes in hypertension: implications for antihypertensive drug therapy. Drugs. 2006; 66: 133-144.
7. Ferrari R. Prognostic benefits of heart rate reduction in cardiovascular disease. Eur Heart J. 2003; 5 (Suppl G): G10-G14.
8. Kannel WB, Kannel C, Paffenbarger RS, Cupples LA. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J. 1987; 113: 1489-1494.
9. Gillum RF, Makuc DM, Feldman JJ. Pulse rate, coronary heart disease, and death: the NHANES I Epidemiologic Follow- up Study. Am Heart J. 1991; 121: 172-177.
10. Giannoglou GD, Chatzizisis YS, Zamboulis C, Parcharidis GE, Mikhailidis DP, Louridas GE. Elevated heart rate and atherosclerosis: an overview of the pathogenetic mechanisms. Int J Cardiol. 2008; 126: 302-312.
11. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet. 2008; 372: 817-821.
12. Fox K, Garcia MA, Ardissino D, et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J. 2006; 27: 1341-1381.
13. Freemantle N, Cleland J, Young P, Mason J, Harrison J. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999; 318: 1730-1737.
14. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 1998; 339: 489-497.
15. Chafin CC, Soberman JE, Demirkan K, Self T. Beta-blockers after myocardial infarction: do benefits ever outweigh risks in asthma? Cardiology. 1999; 92: 99-105.
16. Viskin S, Barron HV. Beta blockers prevent cardiac death following a myocardial infarction: so why are so many infarct survivors discharged without beta blockers? Am J Cardiol. 1996; 78: 821-822.
17. Soumerai SB, McLaughlin TJ, Spiegelman D, Hertzmark E, Thibault G, Goldman L. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA. 1997; 277: 115-121.
18. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J. 2009; 30: 2337-2345.
19. Egred M, Shaw S, Mohammad B, Waitt P, Rodrigues E. Under- use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease. QJM. 2005; 98: 493-497.
20. Heller DA, Ahern FM, Kozak M. 2000. Changes in rates of beta-blocker use between 1994 and 1997 among elderly survivors of myocardial infarction. Am Heart J. 2000; 140: 663-671.
21. Chen J, Radford MJ, Wang Y, Marciniak TA, Krumholz HM. Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Am Coll Cardiol. 2001; 37: 1950-1956.
22. Tzanakis N, Anagnostopoulou U, Filaditaki V, Christaki P, Siafakas N. Prevalence of COPD in Greece. Chest. 2004; 125: 892-900.
23. Andrikopoulos G, Pipilis A, Goudevenos J, et al. Epidemiological characteristics, management and early outcome of acute myocardial infarction in Greece: the HELlenic Infarction Observation Study. Hellenic J Cardiol. 2007; 48: 325-334.
24. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007; 176: 532-555.
25. Maragiannis D, Lazaros G, Vavuranakis M, et al. Chronic stable angina: percutaneous coronary intervention or medication? Hellenic J Cardiol. 2011; 52: 246-252.
26. Chatzistamatiou EI, Moustakas GN, Rodolakis NE, Liakos CI, Avgeropoulou CC, Kallikazaros IE. Stable coronary artery disease: latest data in the battle between conservative and invasive management. Hellenic J Cardiol. 2011; 52: 516-524.
27. Antonelli Incalzi R, Fuso L, De Rosa M, et al. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J. 1997; 10: 2794-2800.
28. Daly CA, Clemens F, Sendon JL, et al. Inadequate control of heart rate in patients with stable angina: results from the European heart survey. Postgrad Med J. 2010; 86: 212-217.
29. Vitale C, Iellamo F, Volterrani M, et al. Heart rate control in an unselected consecutive population of outpatients with stable coronary artery disease: Analysis of the CARDIf Study Cohort. Angiology. 2010; 61: 763-767.
30. Ferrari R, Ford I, Fox K, Steg PG, Tendera M. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. Cardiology. 2008; 110: 271-282.
31. Gibbons RJ, Abrams J, Chatterjee K, et al; American College of Cardiology; American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol. 2003; 41: 159-168.
32. Cucherat M. Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in postmyocardial infarction: a meta-regression of randomized clinical trials. Eur Heart J. 2007; 28: 3012-3019.
33. McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med. 2009; 150: 784-794.
34. Böhm M, Swedberg K, Komajda M, et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet. 2010; 376: 886-894.
35. Diaz A, Bourassa MG, Guertin MC, Tardif JC. Long term prog nostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J. 2005: 26: 967-974.
36. Palatini P, Casiglia E, Julius S, Pessina AC. High heart rate: a risk factor for cardiovascular death in elderly men. Arch Intern Med. 1999; 159: 585-592.
37. Schwartz PJ, Priori SG. Sympathetic nervous system and cardiac arrhythmias. In: Zipes DP, Jalife J, editors. Cardiac Electrophysiology: From Cell to Bedside. Philadelphia, Pa: WB Saunders Co; 1990: p. 330-343.
38. Hohnloser SH, Klingenheben T, van de Loo A, Hablawetz E, Just H, Schwartz PJ. Reflex versus tonic vagal activity as a prognostic parameter in patients with sustained ventricular tachycardia or ventricular fibrillation. Circulation. 1994; 89: 1068-1073.
39. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998; 339: 229-334.
40. Panagiotakos DB, Pitsavos C, Chrysohoou C, Skoumas I, Stefanadis C. Prevalence and five-year incidence (2001-2006) of cardiovascular disease risk factors in a Greek sample: the ATTICA study. Hellenic J Cardiol. 2009; 50: 388-395.
41. Miettinen H, Lehto S, Salomaa V, et al. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care. 1998; 21: 69-75.
42. Facchini FS, Stoohs RA, Reaven GM. Enhanced sympathetic nervous system activity. The linchpin between insulin resistance, hyperinsulinemia, and heart rate. Am J Hypertens. 1996; 9: 1013-1017.
43. Grassi G, Vailati S, Bertinieri G, et al. Heart rate as marker of sympathetic activity. J Hypertens. 1998; 16: 1635-1639.
44. Linnemann B, Janka HU. Prolonged QTc interval and elevated heart rate identify the type 2 diabetic patient at high risk for cardiovascular death. The Bremen Diabetes Study. Exp Clin Endocrinol Diabetes. 2003; 111: 215-222.
45. Stettler C, Bearth A, Allemann S, et al. QTc interval and resting heart rate as long-term predictors of mortality in type 1 and type 2 diabetes mellitus: a 23-year follow-up. Diabetologia. 2007; 50: 186-194.